Rockwell Medical, Inc. (NASDAQ:RMTI) is set to announce third quarter earning results on Monday 9th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, RMTI to report 3Q20 loss of $ 0.1 per share.
For the full year, analysts anticipate top line of $ 66.61 million, while looking forward to loss of $ 0.4 per share bottom line.
Previous Quarter Performance
Rockwell Medical, Inc. posted loss for the second quarter of $ 0.09 per share, from the revenue of $ 15.90 million. The quarterly revenues dropped 3.05 percent compared with the same quarter last year. Street analysts expected Rockwell Medical, Inc. to report loss of $ 0.14 per share on revenue of $ 14.41 million for the second quarter. The bottom line results beat street analysts by $ 0.05 or 35.71 percent, at the same time, top line results outshined analysts by $ 1.49 million or 10.34 percent.
Stock Performance
On Friday, shares of Rockwell Medical, Inc. has traded high as $ 0.92 and has cracked $ 0.88 on the downward trend, reaching $ 0.89 with volume of 428.20 thousand shares.
According to the previous trading day, closing price of $ 0.89, representing a 10.84 % increase from the 52 week low of $ 0.83 and a 76.1 % decrease over the 52 week high of $ 3.85.
The company has a market capital of $ 81.52 million and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Conference Call
Rockwell Medical, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.rockwellmed.com
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
